-
公开(公告)号:US20220274939A1
公开(公告)日:2022-09-01
申请号:US17631212
申请日:2021-07-28
Applicant: Vivozon Inc.
Inventor: Dae Kyu CHOI , Hyo Jin KIM , Mi Seon BAE , Jin CHOI , Hyun Jin HEO , Yong Seok LEE , Geon Ho LEE , Mi Yon SHIM , Jin Sun PARK , Han Mi LEE
IPC: C07D295/135 , A61P25/04 , C07D213/56 , C07C237/34 , C07D309/14 , C07D213/40 , C07D307/14 , C07D319/12 , C07D309/06 , C07C233/66 , C07D305/06 , C07C233/86 , C07C233/72 , C07C233/78 , C07C233/70
Abstract: Disclosed are a dual modulator of mGluR5 and 5-HT2AR (5-HT2A receptor), and use thereof. More specifically, disclosed are a compound which acts as modulator of mGluR5 and an antagonist of 5-HT2AR at the same time, and use thereof as therapeutic agent for pain.
-
公开(公告)号:US20240360092A1
公开(公告)日:2024-10-31
申请号:US18760458
申请日:2024-07-01
Applicant: Vivozon Inc.
Inventor: Dae Kyu CHOI , Hyo Jin KIM , Mi Seon BAE , Jin CHOI , Hyun Jin HEO , Yong Seok LEE , Geon Ho LEE , Mi Yon SHIM , Jin Sun PARK , Han Mi LEE
IPC: C07D295/135 , A61P25/04 , C07C233/66 , C07C233/70 , C07C233/72 , C07C233/78 , C07C233/86 , C07C237/34 , C07D213/40 , C07D213/56 , C07D305/06 , C07D307/14 , C07D309/06 , C07D309/14 , C07D319/12
CPC classification number: C07D295/135 , A61P25/04 , C07C233/66 , C07C233/70 , C07C233/72 , C07C233/78 , C07C233/86 , C07C237/34 , C07D213/40 , C07D213/56 , C07D305/06 , C07D307/14 , C07D309/06 , C07D309/14 , C07D319/12
Abstract: Disclosed are a dual modulator of mGluR5 and 5-HT2AR (5-HT2A receptor), and use thereof. More specifically, disclosed are a compound which acts as modulator of mGluR5 and an antagonist of 5-HT2AR at the same time, and use thereof as therapeutic agent for pain.
-
公开(公告)号:US20220233492A1
公开(公告)日:2022-07-28
申请号:US17596397
申请日:2020-06-19
Applicant: Vivozon Inc.
Inventor: Doo Hyun LEE , Sunyoung CHO
IPC: A61K31/351 , A61P29/00
Abstract: A method for treating or preempting pain including postoperative pain following a soft or hard tissue surgery is disclosed. Also disclosed is a method for reducing an postoperative analgesic need, including administering a compound of Formula (I) or a salt thereof.
-
公开(公告)号:US20230041556A1
公开(公告)日:2023-02-09
申请号:US17787998
申请日:2020-12-22
Applicant: Vivozon, Inc.
Inventor: Il Kyu YOON
Abstract: The present invention relates to a colonic purgative composition and a preparation method therefor, and more specifically, to a colonic purgative composition comprising sodium picosulfate, potassium sulfate and magnesium sulfate, and a preparation method therefor.
-
公开(公告)号:US09359346B2
公开(公告)日:2016-06-07
申请号:US14361638
申请日:2012-11-29
Applicant: VIVOZON, INC.
Inventor: Doo Hyun Lee , Myung Soo Ham , Ji-Hyun Lee
IPC: A61K31/47 , C07D295/12 , C07D217/22 , C07D211/26 , C07D413/04 , C07D211/58 , C07D207/09 , C07D455/02 , C07D285/12 , C07D405/04 , C07D211/44 , C07D207/14 , C07D453/02 , C07D309/14 , C07D215/38 , C07C235/50 , C07C235/54 , C07D211/34 , C07D295/15
CPC classification number: C07D453/02 , A61K31/47 , C07C235/50 , C07C235/54 , C07D207/09 , C07D207/14 , C07D211/26 , C07D211/34 , C07D211/44 , C07D211/58 , C07D215/38 , C07D217/22 , C07D285/12 , C07D295/12 , C07D295/15 , C07D309/14 , C07D405/04 , C07D413/04 , C07D455/02
Abstract: Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc. Further, since it was demonstrated that the present invention displays anti-pruritic efficacy even in an itching model, to which a mechanism and treatment concept established with respect to pain is applied, the present invention may also be effectively used in radical treatment of atopic dermatitis by applying the inventive product to an anti-pruritic composition in order to suppress an initial itching stage and treat symptoms thereof, thus preventing skin damage or inflammation after the scratching stage.
Abstract translation: 公开了一种新型的苯甲酰胺衍生物及其药物用途,更具体地说,涉及具有式1结构的新型苯甲酰胺衍生物或其药学上可接受的盐,以及用于预防或治疗包括上述物质的疼痛或瘙痒的组合物。 根据本发明的新型苯甲酰胺衍生物及其药学上可接受的盐在神经病动物模型中表现出优异的疼痛抑制作用,特别是疼痛抑制作用,但也表现出其它模型如福尔马林模型,因此可能 用于抑制不良疼痛,例如伤害性疼痛,慢性疼痛等。此外,由于证明本发明即使在瘙痒模型中也显示抗瘙痒功效,其中针对疼痛建立了机制和治疗概念 本发明也可以有效地用于通过将本发明产品应用于抗瘙痒组合物进行自身治疗特应性皮炎,以抑制初始瘙痒期并治疗其症状,从而防止皮肤损伤或刮伤后的炎症 阶段。
-
公开(公告)号:US12060339B2
公开(公告)日:2024-08-13
申请号:US17631212
申请日:2021-07-28
Applicant: Vivozon Inc.
Inventor: Dae Kyu Choi , Hyo Jin Kim , Mi Seon Bae , Jin Choi , Hyun Jin Heo , Yong Seok Lee , Geon Ho Lee , Mi Yon Shim , Jin Sun Park , Han Mi Lee
IPC: C07D295/135 , A61P25/04 , C07C233/66 , C07C233/70 , C07C233/72 , C07C233/78 , C07C233/86 , C07C237/34 , C07D213/40 , C07D213/56 , C07D305/06 , C07D307/14 , C07D309/06 , C07D309/14 , C07D319/12
CPC classification number: C07D295/135 , A61P25/04 , C07C233/66 , C07C233/70 , C07C233/72 , C07C233/78 , C07C233/86 , C07C237/34 , C07D213/40 , C07D213/56 , C07D305/06 , C07D307/14 , C07D309/06 , C07D309/14 , C07D319/12
Abstract: Disclosed are a dual modulator of mGluR5 and 5-HT2AR (5-HT2A receptor), and use thereof. More specifically, disclosed are a compound which acts as modulator of mGluR5 and an antagonist of 5-HT2AR at the same time, and use thereof as therapeutic agent for pain.
-
公开(公告)号:US20140336378A1
公开(公告)日:2014-11-13
申请号:US14361638
申请日:2012-11-29
Applicant: VIVOZON, INC.
Inventor: Doo Hyun Lee
IPC: C07D453/02 , C07D215/38 , C07C235/54 , C07D309/14 , C07C235/50 , C07D295/15 , C07D211/34
CPC classification number: C07D453/02 , A61K31/47 , C07C235/50 , C07C235/54 , C07D207/09 , C07D207/14 , C07D211/26 , C07D211/34 , C07D211/44 , C07D211/58 , C07D215/38 , C07D217/22 , C07D285/12 , C07D295/12 , C07D295/15 , C07D309/14 , C07D405/04 , C07D413/04 , C07D455/02
Abstract: Disclosed are a novel benzamide derivative and pharmaceutical use thereof, and more particularly, a novel benzamide derivative having a structure of Formula 1 or pharmaceutically acceptable salts thereof, and a composition for prevention or treatment of pain or itching including the above material. The novel benzamide derivative and pharmaceutically acceptable salt thereof according to the present invention exhibit excellent pain-suppressive effect and, in particular, pain-suppressive effect in not only a neuropathic animal model but also other models such as a formalin model, and therefore, may be used in suppression of different pains such as nociceptive pain, chronic pain, etc. Further, since it was demonstrated that the present invention displays anti-pruritic efficacy even in an itching model, to which a mechanism and treatment concept established with respect to pain is applied, the present invention may also be effectively used in radical treatment of atopic dermatitis by applying the inventive product to an anti-pruritic composition in order to suppress an initial itching stage and treat symptoms thereof, thus preventing skin damage or inflammation after the scratching stage.
Abstract translation: 公开了一种新型的苯甲酰胺衍生物及其药物用途,更具体地说,涉及具有式1结构的新型苯甲酰胺衍生物或其药学上可接受的盐,以及用于预防或治疗包括上述物质的疼痛或瘙痒的组合物。 根据本发明的新型苯甲酰胺衍生物及其药学上可接受的盐在神经病动物模型中表现出优异的疼痛抑制作用,特别是疼痛抑制作用,但也表现出其它模型如福尔马林模型,因此可能 用于抑制不良疼痛,例如伤害性疼痛,慢性疼痛等。此外,由于证明本发明即使在瘙痒模型中也显示抗瘙痒功效,其中针对疼痛建立了机制和治疗概念 本发明也可以有效地用于通过将本发明产品应用于抗瘙痒组合物进行自身治疗特应性皮炎,以抑制初始瘙痒期并治疗其症状,从而防止皮肤损伤或刮伤后的炎症 阶段。
-
-
-
-
-
-